ArticleBasic research in cardiology2021
Translation of experimental cardioprotective capability of P2Y
Article in Basic research in cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Effect of ticagrelor and prasugrel on remote myocardial inflammation in patients with acute myocardial infarction with ST-elevation: a CMR T1 and T2 mapping study.The international journal of cardiovascular imaging · 2023Trial
- Assessment of myocardial salvage in patients with STEMI undergoing thrombolysis: ticagrelor versus clopidogrel.BMC cardiovascular disorders · 2022Trial
- Effects of ischemic conditioning on head and neck free flap oxygenation: a randomized controlled trial.Scientific reports · 2022Trial
- Prevention of In-Stent Restenosis After PCI by Saponin Natural Products: Inhibition of Platelet Activation.Journal of cellular and molecular medicine · 2026Review
- A Comprehensive Review of the Pleiotropic Effects of Ticagrelor.Cardiovascular drugs and therapy · 2024Review
- Platelet-Mediated Transfer of Cardioprotection by Remote Ischemic Conditioning and Its Abrogation by Aspirin But Not by Ticagrelor.Cardiovascular drugs and therapy · 2023Article
- Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning.Pharmacological reviews · 2023Review
- Do We Really Need Aspirin Loading for STEMI?Cardiovascular drugs and therapy · 2022Review
- Pharmacological Approaches to Limit Ischemic and Reperfusion Injuries of the Heart: Analysis of Experimental and Clinical Data on P2YKorean circulation journal · 2022Review
- Low-dose and standard-dose ticagrelor compared with clopidogrel in patients with acute coronary syndromes: A cohort study from china.Frontiers in cardiovascular medicine · 2022Article
- The Role of Purinergic Signaling in Heart Transplantation.Frontiers in immunology · 2022Review
- GSDMD contributes to myocardial reperfusion injury by regulating pyroptosis.Frontiers in immunology · 2022Article
- The platelet paradox of injury versus protection in myocardial infarction-has it been overlooked?Basic research in cardiology · 2021Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 5 institutions in 3 countries.
Funding
Abstract
We studied the translational cardioprotective potential of P2Y
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.